Financial Data and Key Metrics Changes - R&D expenses decreased to approximately $2.4 million for Q3 2025 from $3.7 million in Q3 2024, primarily due to reductions in clinical trial support and consulting expenses [38] - General and administrative expenses increased to approximately $1.9 million in Q3 2025 from $1.5 million in the prior year, attributed to higher business development and investor relations costs [38] - The net loss for Q3 2025 was approximately $4.2 million, or $0.39 per share, compared to a net loss of approximately $4.5 million, or $0.42 per share in Q3 2024 [39] Business Line Data and Key Metrics Changes - The LP-184 phase 1a clinical trial achieved a 48% clinical benefit rate in evaluable cancer patients, demonstrating significant tumor reductions in patients with specific DNA-damage repair mutations [5][10] - Preliminary phase II data from the LP-300 Harmonic trial showed an 86% clinical benefit rate, with one patient demonstrating a durable complete response lasting nearly two years [21] Market Data and Key Metrics Changes - The combined annual market potential for the targeted indications of LP-184 exceeds $7 billion, focusing on triple-negative breast cancer, non-small cell lung cancer, bladder cancer, and recurrent GBM [17] - The market opportunity for lung cancer in never-smokers is approaching $4 billion annually, with no current therapies approved for this demographic [19] Company Strategy and Development Direction - The company is focused on integrating AI and machine learning into drug development, positioning itself as a leader in precision oncology [4][36] - The RADR AI platform is being commercialized, with eight distinct AI-powered modules developed to address critical pain points in oncology drug development [27][36] - The introduction of the Zeta platform aims to streamline rare cancer research and drug development by integrating fragmented data sources into a cohesive AI system [30][34] Management's Comments on Operating Environment and Future Outlook - Management highlighted the transformative nature of the past quarter, achieving multiple clinical, regulatory, and validation milestones [5] - The company expects to continue advancing its clinical assets while scaling its AI platform for commercial deployment, emphasizing a dual engine strategy [43] Other Important Information - As of September 30, 2025, the company had approximately $12.4 million in cash, cash equivalents, and marketable securities, providing a runway into Q3 2026 [39] - The company entered into an ATM sales agreement to offer and sell up to $15.53 million of its common stock, raising approximately $989,000 during Q3 2025 [40] Q&A Session Summary Question: Tracking toward an interim event analysis for the LP-300 trial - Management indicated that they do not believe they will reach the 31 events required for the analysis, which is positive as it suggests patients are remaining on the trial longer [44] Question: Status of the Denmark trial - The Denmark trial has been approved, with IRBs set and a project manager assigned, expected to start in late December or early January [45] Question: IND submission for the pediatric CNS program - Management confirmed readiness to submit the IND for the pediatric CNS program in the coming weeks [45] Question: Updates on the Zeta platform - The Zeta platform is expected to have an early rollout with demos available to collaborators and partners, with broader rollout planned for Q1 2026 [46] Question: Indications for LP-184 - Management plans to identify the most impactful indications for larger scale trials, with interest from pharmaceutical companies [47] Question: Development of Zeta - Zeta was initially developed to address rare cancers, with the goal of providing a comprehensive tool for drug developers [48]

Financial Data and Key Metrics Changes - R&D expenses decreased to approximately $2.4 million in Q3 2025 from $3.7 million in Q3 2024, primarily due to reductions in clinical trial support and consulting expenses [38] - General and administrative expenses increased to approximately $1.9 million in Q3 2025 from $1.5 million in the prior year, attributed to higher business development and investor relations costs [38] - The net loss for Q3 2025 was approximately $4.2 million, or $0.39 per share, compared to a net loss of approximately $4.5 million, or $0.42 per share in Q3 2024 [39] Business Line Data and Key Metrics Changes - The LP-184 phase I-A clinical trial achieved a 48% clinical benefit rate in evaluable cancer patients, validating the AI-driven precision medicine approach [5][10] - The LP-300 Harmonic trial showed an 86% clinical benefit rate in preliminary data, with one patient demonstrating a durable complete response for nearly two years [21] - The LP-284 program for recurrent non-Hodgkin's lymphoma generated interest from biopharma companies, showcasing a complete metabolic response in a heavily pretreated patient [23] Market Data and Key Metrics Changes - The combined annual market potential for the targeted indications of LP-184 exceeds $7 billion, focusing on triple-negative breast cancer, non-small cell lung cancer, bladder cancer, and recurrent GBM [17] - The market opportunity for the LP-300 trial in never-smokers with lung cancer is approaching $4 billion annually, with no current approved therapies for this demographic [19] - The LP-284 program has a global market opportunity of about $3 billion, targeting aggressive recurrent non-Hodgkin's lymphoma [22] Company Strategy and Development Direction - The company is focused on integrating AI and machine learning into drug discovery and development, positioning itself as a leader in precision oncology [4] - The RADR AI platform is being commercialized, with eight distinct AI-powered modules developed to address critical pain points in oncology drug development [27] - The introduction of the Zeta platform aims to streamline rare cancer research and drug development, enhancing the efficiency of identifying treatment options [30][34] Management's Comments on Operating Environment and Future Outlook - Management highlighted the transformative nature of the past quarter, achieving significant clinical, regulatory, and validation milestones [5] - The company expects to continue advancing its clinical assets while scaling its AI platform for commercial deployment, emphasizing a dual engine strategy [43] - Management expressed confidence in the potential of their AI tools and services, projecting significant standalone market potential in the future [36] Other Important Information - The company had approximately $12.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing a runway into Q3 2026 [39] - The company entered into an ATM sales agreement to offer and sell up to $15.53 million of its common stock, raising approximately $989,000 during Q3 2025 [40] Q&A Session Summary Question: What is the status of the interim event analysis for the LP-300 trial? - Management indicated that they do not believe they will reach the 31 events required for the analysis by December, which is positive as it suggests patients are remaining on the trial longer [45] Question: What is the timeline for the Denmark trial? - The Denmark trial has been approved, and management expects it to start in late December or early January [45] Question: What is the status of the IND submission for the pediatric CNS program? - Management confirmed that they are prepared to submit the IND for the pediatric CNS program in the coming weeks [46] Question: What can be expected from the Zeta platform? - Management mentioned that Zeta will be rolled out in phases, with early demos available to collaborators and partners, and broader rollout expected in Q1 2026 [46] Question: How will the indications for LP-184 be prioritized? - Management plans to evaluate which indications yield the biggest impact and move those into larger scale trials, ideally with partners [47]

Financial Data and Key Metrics Changes - R&D expenses decreased to approximately $2.4 million in Q3 2025 from $3.7 million in Q3 2024, primarily due to reductions in clinical trial support and consulting expenses [35] - General and administrative expenses increased to approximately $1.9 million in Q3 2025 from $1.5 million in the prior year, attributed to higher business development and investor relations costs [35] - The net loss for Q3 2025 was approximately $4.2 million, or $0.39 per share, compared to a net loss of approximately $4.5 million, or $0.42 per share in Q3 2024 [36] Business Line Data and Key Metrics Changes - The LP-184 phase 1a clinical trial achieved a 48% clinical benefit rate in evaluable cancer patients, validating the AI-driven precision medicine approach [5][11] - Preliminary phase II data from the LP-300 Harmonic trial showed an 86% clinical benefit rate, with one patient demonstrating a durable complete response for nearly two years [20][21] - The LP-284 program targeting recurrent non-Hodgkin's lymphoma generated interest from biopharma companies, showcasing a complete metabolic response in a heavily pretreated patient [23] Market Data and Key Metrics Changes - The combined annual market potential for the targeted indications of LP-184 exceeds $7 billion, with specific opportunities in triple-negative breast cancer, non-small cell lung cancer, bladder cancer, and recurrent GBM [17] - The market opportunity for the LP-300 program in lung cancer among never-smokers is approaching $4 billion annually, with no current approved therapies for this demographic [19] - The LP-284 program has a global market opportunity of about $3 billion, focusing on patients with aggressive recurrent non-Hodgkin's lymphoma [22] Company Strategy and Development Direction - The company is focused on integrating AI and machine learning into drug discovery and development, positioning itself as a leader in precision oncology [4][39] - The RADR AI platform is being commercialized, with eight distinct AI-powered modules developed to address critical pain points in oncology drug development [26][34] - The introduction of the Zeta platform aims to streamline rare cancer research and drug development, enhancing decision-making and reducing costs [30][32] Management's Comments on Operating Environment and Future Outlook - Management highlighted the transformative nature of the past quarter, achieving significant clinical, regulatory, and validation milestones [5] - The company expects to continue advancing its clinical assets while scaling its AI platform for commercial deployment, emphasizing a dual engine strategy [39][40] - Management expressed confidence in the potential of their AI tools and services to represent several hundred million dollars in standalone market potential [34] Other Important Information - As of September 30, 2025, the company had approximately $12.4 million in cash, cash equivalents, and marketable securities, providing a runway into approximately Q3 2026 [36] - The company entered into an ATM sales agreement to offer and sell up to $15.53 million of its common stock, raising approximately $989,000 during Q3 2025 [37] Q&A Session Summary Question: Update on interim event analysis for the LP-300 trial - Management indicated that they do not expect to reach the 31 events required for analysis until early 2026, which is seen as positive news as it suggests patients are remaining on the trial longer [41] Question: Status of the Denmark trial - The Denmark trial has been approved, with IRBs set and a project manager assigned, expected to start in late December or early January [42] Question: IND submission for the pediatric CNS program - Management confirmed readiness to submit the IND for the pediatric CNS program in the coming weeks [42] Question: Details on the Zeta platform - The Zeta platform is expected to have an interesting and bumpy early rollout, with internal usage already underway and plans for broader rollout in Q1 [43] Question: Indications for LP-184 - Management plans to identify the most impactful indications for larger scale trials, with interest from pharmaceutical companies [44]

Core Insights - The latest industry data indicates that the South Korean-developed AI chatbot application Zeta has surpassed ChatGPT to become the most used AI chat application in South Korea [1] Usage Statistics - According to market analysis firm Wiseapp Retail, Zeta achieved a total user interaction time of 73.62 million hours in October 2023 [1] - In comparison, OpenAI's ChatGPT recorded 48.28 million hours of user interaction during the same period [1]

Lantern Pharma Conference Call Summary Company Overview - **Company**: Lantern Pharma (NasdaqCM: LTRN) - **Focus**: AI-driven drug development, particularly in oncology, utilizing proprietary AI platforms to identify and develop targeted therapies [1][2] Key Points and Arguments AI and Drug Development - Lantern Pharma has developed **12 drug programs** since late 2018, with **three currently in clinical trials** [2] - The company emphasizes the use of AI to accelerate drug discovery, aiming to make the process faster and more cost-effective [2][3] - The AI platform has evolved significantly, reducing the time to update and improve its capabilities from over a year to less than four months [6][16] Clinical Trials and Drug Candidates - **LP-300**: Targeting lung cancer in non-smokers, currently in Phase 2 trials. This demographic represents about **17% of lung cancer cases in the U.S.** and **35-40% in East Asia** [5][27] - **LP-284**: A drug for non-Hodgkin's lymphoma showing complete metabolic response in trials. It is positioned as a potential blockbuster with a market potential of over **$10 billion** [6][31] - **LP-184**: Targets cancers with DNA damage repair deficiencies, with a market potential of over **$4 billion**. It has shown promising results in various cancers, including lung and triple-negative breast cancer [32][27] Business Model and Market Strategy - Lantern Pharma's business model includes repositioning existing drugs and developing new ones, with a focus on precision oncology [4][9] - The company plans to monetize its AI platform through a **freemium model**, allowing other cancer drug developers to access its technology [7][19] - The company is also preparing to spin out **Starlight Therapeutics**, focusing exclusively on brain cancers, which could enhance its market valuation [11][12] Financials and Market Position - As of the last quarter, Lantern Pharma reported approximately **$15.9 million** in cash with a burn rate of **$4 to $4.5 million** per quarter [36] - The company has not raised capital since January 2021 and has no toxic financial events or warrants [36] Regulatory Environment - The FDA is increasingly focusing on AI models in drug development, which could benefit Lantern Pharma's initiatives, especially in pediatric cancers [36][37] - Lantern has received multiple rare pediatric designations, enhancing its potential for market success [37] Additional Important Insights - The company is actively engaging with pharmaceutical companies for potential partnerships, although challenges exist due to industry skepticism towards AI [21][22] - Lantern Pharma's approach to drug development is characterized by a willingness to explore multiple avenues simultaneously, reflecting a strategy to mitigate risks in a highly uncertain field [24][26] - The company believes that the future of medicine will increasingly rely on AI, positioning itself as a leader in this transformative space [27] This summary encapsulates the critical aspects of Lantern Pharma's conference call, highlighting its innovative approach to drug development, clinical advancements, and strategic positioning in the oncology market.